|
The total income for the third quarter ended 31st
December 2004 stood at Rs. 323.34 crore
(Rs.325.39 crore) and the net profit after
taxation stood at Rs.10.59 crore (Rs.35.62 crore).
During Q2 FY04-05, the total income and net
profit after taxation were Rs.271.98 crore and
Rs.2.56 crore respectively. When compared with
Q2 FY04-05 results, the total income in Q3 FY
04-05 was up by 18.88 % and net profit after tax
was up by 313.68%. |
|
During the quarter, higher interest of Rs.10.42
crore (Rs.7.81 crore) and depreciation of
Rs.12.58 crore (Rs.9.09 crore) were absorbed.
These higher expenses were on account of
investments in R&D and production infrastructure
for regulatory markets. |
|
The Company has also written off R&D expenditure
of Rs.10.37 crore (Rs.8.14 crore) during the
quarter. |
|
The Company has accelerated the DMF/ANDA filings
programme and the Q3 FY04-05 witnessed 11 DMFs
filings (cumulative 64) and 5 ANDA/Formulation
dossier filings (cumulative 15) in the US/EU. In
US itself, the Company has filed 7 DMFs
(cumulative 22) and 5 ANDAs (cumulative 11) in
Q3. |
|
During the quarter, another major milestone has
been crossed in its foray into the regulated
markets with the successful inspection and audit
of the manufacturing facility - Unit 8 by USFDA
without receiving any Form 483 queries. The Unit
8 located near Hyderabad, manufactures Active
Pharmaceutical Ingredients (API) and comprises 3
manufacturing blocks. The company has filed 6
Drug Master Files (DMFs) from this unit in the
therapeutic segments of CVS, CNS and Anti
Retrovirals. |
|
Aurobindo receives USFDA approval for Metformin: |
|
Aurobindo Pharma Limited is pleased to announce
that USFDA (U.S. Food and Drug Administration)
has granted approval for its Abbreviated New
Drug Application (ANDA) for Metformin.
Metformin is
indicated in the treatment of diabetes. |
|
Both API and Formulation shall be manufactured
in the Company’s Units and Aurobindo has
distinctive advantage of complete vertical
integration in this product in India. With this
approval, Aurobindo Pharma has received its 3rd
product approval from USFDA for marketing in the
USA and looks forward for more to come in the
near future. |
|
The product is one among the top products in
terms of volume in USA. |
|
Aurobindo has invested significant resources in
building a mega infrastructure for API’s and
Formulations to emerge as a vertically
integrated pharmaceutical company. Aurobindo’s 4
units for API’s and 4 Units for Formulations,
are designed for the Regulated market. The
Company expects to reap the benefits of
continuous product approvals from US/EU in the
coming quarters. |
PRESS
ROOM 
